Article Listing
Transgene signs billion dollar deal with Novartis for TG4010 cancer vaccine option, but still disappoints investors
11 March 2010
Transgene has signed an exclusive option agreement with Swiss drug major Novartis for the development and commercialization of the French biotechnology firm’s targeted cancer vaccine TG4010 (MVA-MUC1-IL2), for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications.
AstraZeneca pushes further into emerging market with Torrent deal
11 March 2010
Confirming its ongoing interest in emerging markets, Anglo-Swedish drug major AstraZeneca has entered into a license and supply agreement with India’s Torrent Pharmaceuticals for the latter to supply a portfolio of generic medicines for which Torrent already has licenses in a range of countries. Working in partnership with Torrent, AstraZeneca says it intends to brand and market these products in many of its emerging markets, where it already has a strong commercial footprint.
US generic drugmakers urge more funding of FDA, especially OGD division
11 March 2010
The Generic Pharmaceutical Association (GPhA) has reiterated its appeal for additional funding of the Food and Drug Administration in order that copy medicines can come to the market more quickly, as the anticipated drug “patent cliff” floods the agency with ever more applications.
Takeda enters settlement with Watson over Actos patent challenge; pays milestone in Affymax deal
11 March 2010
In what is another deal that is designed to delay the entry of a copy drug on to the US market, Watson Pharmaceuticals says that it has reached a settlement agreement with Japan’s largest drugmaker Takeda, and its US subsidiary Takeda Pharmaceuticals North America, resolving outstanding patent litigation related to Watson's generic equivalent version of the type 2 diabetes drug Actos (pioglitazone) 15mg, 30mg and 45mg tablets.
A tale of two markets: Obesity and type 2 diabetes sectors closely linked but vastly different in outlook
11 March 2010
Rising obesity levels across the western world could result in a near doubling of the type 2 diabetes drug market by 2018, according to Datamonitor. The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008.
Cellzome in up to 508 million-euro deal with GlaxoSmithKline on inflammatory disease
11 March 2010
Anglo-German firm Cellzome says it has formed a second strategic alliance with UK drug giant GlaxoSmithKline providing the latter with exclusive access to Cellzome's proprietary Episphere technology in the emerging field of epigenetics as applied to immune-inflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
Korea’s Celltrion develops of broad spectrum human MAb against major flu viruses (H1N1 and H5N1)
11 March 2010
infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.
Antisense Pharma gets added patent protection for trabedersen until 2026; raises 13 million euros
11 March 2010
The European Patent Office has granted German biopharmaceutical company Antisense Pharma additional patent protection for the use of its flagship product trabedersen until 2026. This gives Antisense a comprehensive marketing exclusivity for the use of this drug within the settings of tumor-illnesses, central nervous system diseases and immunosuppression, taking into consideration the effective dose.
Generics poised to drive pharmaceutical market in Botswana, as govt aims to create an indigenous industry
11 March 2010
The land-locked African nation of Botswana does not yet have a pharmaceutical manufacturing industry and thus, all drugs are imported. In an attempt to improve accessibility to essential medication and diversify economic activity, the government is launching private-public partnership (PPP) initiatives to kick-start local pharmaceutical production, according to a new report from Frost & Sullivan.
HIV drug study ACTG5202 overview by Anton Pozniak
11 March 2010
One of the largest-ever HIV trials - ACT5202, a trial carried out by the AIDS Clinical Trial Group (ACTG) which was created in 1987 by the U. based National Institute of Allergy and Infectious Disease (NIAID) to broaden the scope of its AIDS research effort - reported its findings to the Conference of Retroviruses and Opportunistic Infections (CROI) held in San Francisco, USA.
- France's drug levy meets CNAM targets
- Mexico’s pharmaceuticals market forecast to grow to $14.9 billion by 2014
- Fixed-dose combo of telmisartan/amlodipine “will become clinical gold standard for hypertension” in 2013
- US FDA backs safety of Pfizer/Boehringer’s Spiriva HandiHaler; Pfizer admits EU investigation; gets sued over Chantix
- MDRNA leaps on new bladder and liver anti-tumor drug data and collaborative partner
